Nicole E. De Long
Hamilton, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Increased incidence of non-alcoholic fatty liver disease in male rat offspring exposed to fluoxetine during fetal and neonatal life involves the NLRP3 inflammasome and augmented de novo hepatic lipogenesis.
Journal: Journal of applied toxicology : JAT
Published: April 26, 2017
Early-life chemical exposures and risk of metabolic syndrome.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: April 04, 2017
Fetal Exposure to Sertraline Hydrochloride Impairs Pancreatic β-Cell Development.
Journal: Endocrinology
Published: March 13, 2015
Major depressive disorder and diabetes: does serotonin bridge the gap?
Journal: Current diabetes reviews
Published: December 11, 2014
Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats.
Journal: Toxicology and applied pharmacology
Published: November 08, 2014
Is it safe to use smoking cessation therapeutics during pregnancy?
Journal: Expert opinion on drug safety
Published: October 22, 2014
Angiogenesis in the placenta: the role of reactive oxygen species signaling.
Journal: BioMed research international
Published: July 06, 2014
Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression.
Journal: Journal of affective disorders
Published: April 22, 2014
Postnatal metabolic and reproductive consequences of fetal and neonatal exposure to the smoking cessation drug bupropion.
Journal: Reproductive sciences (Thousand Oaks, Calif.)
Published: February 27, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026